Molecular Mechanisms of Epithelial–Mesenchymal Transition in Retinal Pigment Epithelial Cells: Implications for Age-Related Macular Degeneration (AMD) Progression
Biomolecules · 27.05.2025 · 15 (6) · 771
DOI: 10.3390/biom15060771 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 27.05.2025. Verfasst von Na Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Macular Degeneration, Retinal Pigment Epithelium. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Construction Plan of the Gansu Province Natural Science Foundation Project, Gansu Provincial Intellectual Property Program, Gansu Province Joint Research Fund Project.
Abstract (Originalsprache)
Age-related macular degeneration (AMD), the leading cause of irreversible blindness worldwide, represents a complex neurodegenerative disorder whose pathogenesis remains elusive. At the core of AMD pathophysiology lies the retinal pigment epithelium (RPE), whose epithelial–mesenchymal transition (EMT) has emerged as a critical pathological mechanism driving disease progression. This transformative process, characterized by RPE cell dedifferentiation and subsequent extracellular matrix remodeling, is orchestrated through a sophisticated network of molecular interactions and cellular signaling cascades. Our review provides a comprehensive analysis of the molecular landscape underlying RPE EMT in AMD, with particular emphasis on seven interconnected pathological axes: (i) oxidative stress and mitochondrial dysfunction, (ii) hypoxia-inducible factor signaling, (iii) autophagic flux dysregulation, (iv) chronic inflammatory responses, (v) complement system overactivation, (vi) epigenetic regulation through microRNA networks, and (vii) key developmental signaling pathway reactivation. Furthermore, we evaluate emerging therapeutic strategies targeting EMT modulation, providing a comprehensive perspective on potential interventions to halt AMD progression. By integrating current mechanistic insights with therapeutic prospects, this review aims to bridge the gap between fundamental research and clinical translation in AMD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
- Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou 730000, China.
- Gansu Province Clinical Research Center for Endocrine Disease, Lanzhou 730000, China.
Förderung
- the Construction Plan of the Gansu Province Natural Science Foundation Project
- Gansu Provincial Intellectual Property Program
- Gansu Province Joint Research Fund Project
- National Key R&D program of China
- Lanzhou Municipal Science and Technology Development Guidance Plan Project
- Gansu Province Natural Science Foundation Project
- National Key R&D program of China
Zitieren
APA
Wang, N., Wang, Y., Zhang, L., Yang, W., & Fu, S. (2025). Molecular Mechanisms of Epithelial–Mesenchymal Transition in Retinal Pigment Epithelial Cells: Implications for Age-Related Macular Degeneration (AMD) Progression. Biomolecules, 15(6), 771. https://doi.org/10.3390/biom15060771
Vancouver
Wang N, Wang Y, Zhang L, Yang W, Fu S. Molecular Mechanisms of Epithelial–Mesenchymal Transition in Retinal Pigment Epithelial Cells: Implications for Age-Related Macular Degeneration (AMD) Progression. Biomolecules. 2025;15(6):771. doi:10.3390/biom15060771
BibTeX
@article{Wang2025,
author = {Wang, Na and Wang, Yaqi and Zhang, Lei and Yang, Wenjing and Fu, Songbo},
title = {Molecular Mechanisms of Epithelial–Mesenchymal Transition in Retinal Pigment Epithelial Cells: Implications for Age-Related Macular Degeneration (AMD) Progression},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {6},
pages = {771},
doi = {10.3390/biom15060771}
}
EUVIMED